Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(03): 117-138
DOI: 10.4103/sajc.sajc_57_17
Letter to the Editor

Comparison of the applicability of Hasford score and European Treatment and Outcome Study score in Indian patients with chronic phase chronic myeloid leukemia on imatinib therapy

Neha Chopra Narang
Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi
,
Mrinalini Kotru
Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi
,
Meera Sikka
Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi
,
Usha Rusia
Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Usman M, Syed NN, Kakepoto GN, Adil SN, Khurshid M. Chronic phase chronic myeloid leukemia: Response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response. J Assoc Physicians India 2007;55:103-7.
  • 2 Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 2011;118:686-92.
  • 3 Xia L, Qian W, Yang M, Li Q, Liu F, Xie Y, et al. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy. Onco Targets Ther 2015;8:2485-92.
  • 4 Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, et al. European treatment and outcome study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci 2014;105:105-9.